Moderna (MRNA) ended the recent trading session at $31.25, demonstrating a -2.95% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.01%. Elsewhere, the Dow ...

Moderna has a deep pipeline of promising mRNA candidates that stand to boost business. Regeneron is looking at label ...

Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates May 01, 2025 6:30 AM ET Moderna, Inc. (MRNA) ...

CAMBRIDGE, MA / ACCESS Newswire / May 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2025. "In the first quarter, we ...

Moderna's RSV vaccine for adults aged 60 years and older has been recently approved in Australia, Switzerland, Taiwan and the UK. First Quarter 2025 Financial Results ...